Taken together, these along with the present findings raise the possibility that combining orally active HMAs such as T-dCyd with BCL-2 antagonists such as ABT-199 may have potential utility in the treatment of relapsed/refractory MDS. The gene discussed is BCL2; the disease is myelodysplastic syndrome.